8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): July 22, 2009

BIOSPECIFICS TECHNOLOGIES CORP.
(Exact name of registrant as specified in its charter)
Delaware	0-19879	11-3054851
(State or Other Jurisdiction	(Commission File Number)	(I.R.S. Employer
Of Incorporation)		Identification No.)
	35 Wilbur Street
	Lynbrook, NY 11563
(Address of Principal Executive Office) (Zip Code)
	516.593.7000
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Introductory Comment

Throughout this Current Report on Form 8-K, the terms "we," "us," "our" and "Company" refer to BioSpecifics Technologies Corp.

ITEM 7.01

REGULATION FD DISCLOSURE

Our President, Thomas L. Wegman, will present to investors at the upcoming CapStone Investments’ Third Annual Small-Cap Investor Conference on Wednesday, July 29, 2009 in Milwaukee, Wisconsin. A copy of the presentation materials is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. A press release regarding the announcement is attached hereto as Exhibit 99.2.

ITEM 9.01.

FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Exhibit No.	Description
99.1	Presentation materials to be used by Thomas L. Wegman, the Company’s President, on July 29, 2009
99.2	Press release dated July 22, 2009

SIGNATURES

                                    Pursuant to the requirements of the Securities Exchange Act of 1934, each registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.   

Date: July 22, 2009	BIOSPECIFICS TECHNOLOGIES CORP.
	(Registrant)
	/s/ Thomas L. Wegman
	Thomas L. Wegman
	President

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation materials to be used by Thomas L. Wegman, the Company’s President, on July 29, 2009
99.2	Press release dated July 22, 2009

EX-99.1

Exhibit 99.1

EX-99.2

BioSpecifics Technologies Corp. to Present at
CapStone Investments’ Third Annual Small-Cap
Investor Conference

LYNBROOK, NY – July 22, 2009 - BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics’ President, Tom Wegman, will present at the upcoming CapStone Investments’ Third Annual Small-Cap Investor Conference on Wednesday, July 29, 2009, at 9:30am CT at the Hyatt Regency in Milwaukee, WI.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company’s website at www.biospecifics.com, or you may use the link: http://www.wsw.com/webcast/capstone/bstc.ob/.

An archived version of the webcast will be available for 90 days on the BioSpecifics website.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX product in Europe.

Contact:

BioSpecifics Technologies Corp.
Thomas L. Wegman, President
(516) 593-7000
thomas_wegman@biospecifics.com